rituximab Archives | Page 4 of 21

Roche published Q1 2021 earnings report

by Bioblast Editor | Apr 21, 2021 | Biosimilars updates

Roche published its Q1 2021 earnings report, noting significant impacts from biosimilars. In particular, Roche attributed a combined sales reduction of CHF 1.6 billion to the impact of rituximab, bevacizumab and trastuzumab biosimilars.

New study investigates use of rituximab in MS

by Bioblast Editor | Jan 8, 2021 | Biosimilars updates

A new study reviews the use of rituximab as an alternative treatment option for the management of multiple sclerosis (MS). While not approved for MS, there is evidence of significant off-label usage of rituximab for the treatment of MS in some Northern European...

Amgen’s Bourdon provides update on Riabni® (biosimilar rituximab) launch

by Bioblast Editor | Dec 24, 2020 | Biosimilars updates

The Centre for Biosimilars interviews Christophe Bourdon, senior VP and general manager of US Oncology at Amgen following FDA approval of Riabni® (biosimilar rituximab). Bourdon stated that Riabni® will be made available through speciality and wholesale distribution,...

FDA approves Riabni®

by Bioblast Editor | Dec 17, 2020 | Biosimilars updates

Amgen announces it has received FDA approval for Riabni® (biosimilar rituximab) for the treatment of Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis and Microscopic Polyangiitis. Riabni® will be launched in the US in...

Samsung Biologics and AstraZeneca abandon rituximab JV

by Bioblast Editor | Nov 19, 2020 | Biosimilars updates

Korean Biomedical Review reports Samsung Biologics and AstraZeneca will liquidate their joint venture Archigen Biotech and discontinue the development of SAIT101, a rituximab biosimilar. The project was discontinued due to a perceived lack of commercial...